Oncology

As part of its “Made in China 2025” industrial plan, China hopes to reinvent its pharmaceutical industry. President Xi Jinping has identified his country’s reliance on foreign drug imports as a critical concern. China’s enormous population, coupled with the rise of disease and illness, make the country a prime market for pharmaceutical companies. Xi plans to improve the Chinese pharmaceutical industry to counter this reliance on foreign firms to tap into the revenue generated by the Chinese market, the second largest pharmaceutical market behind the United States, and to create globally competitive firms. The “Made in China 2025” plan seeks to upgrade China’s economy ...